№ files_lp_3_process_7_068581
File format: docx
Character count: 4546
File size: 1740 KB
Public health information leaflet addressed to parents in Belgium outlining the epidemiology of RSV, the risk of bronchiolitis in infants, and the proposed administration and reimbursement conditions of Nirsevimab during the 2025 RSV season.
Country:
Belgium
Topic:
Prevention of RSV infection and bronchiolitis in infants
Document type:
Public health information leaflet
Target audience:
Parents of newborns and infants
Medical focus:
RSV (Respiratory Syncytial Virus) and bronchiolitis
Preventive product:
Nirsevimab (Beyfortus®)
Related vaccine:
Abrysvo®
Institutions mentioned:
Kind&Gezin; ONE in Wallonia
Period concerned:
RSV season (autumn and winter months)
Start date of measure:
October 1st 2025
Reimbursement conditions:
Social insurance with doctor’s prescription; preferential reimbursement available
Administration setting:
Maternity ward or shortly after birth
Geographical scope:
Belgium
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2019
Region / City:
Hawaii
Topic:
Health, Involuntary Hospitalization
Document Type:
Meeting Minutes
Organization:
Hawaii State Capitol
Author:
Task Force Members
Target Audience:
Health Professionals, Task Force Members, Policymakers
Period of Action:
September 17, 2019 - October 25, 2019
Approval Date:
September 17, 2019
Date of Changes:
October 4, 2019
Author:
Annette McCollough
Document Type:
Medical case studies and clinical records
Facility:
Oakdale Nursing Home
Insurance:
Medicare
Patient Names:
Cora Wilkinson; Sarah White
Dates of Service:
January 6–15, 2014
Clinical Settings:
Skilled nursing facility; Inpatient hospital oncology unit
Primary Diagnoses:
Cellulitis of left foot; Neutropenic sepsis; Non-Hodgkin’s lymphoma; Pancytopenia; Hypertension
Treatments:
IV antibiotics; Platelet and blood transfusions; Neupogen injections; Reverse isolation
Medications Mentioned:
Insulin 70/30; Vancomycin; Fortaz; Gentamicin; Cipro; Floxin; Mycostatic; Penicillin; Benadryl; Steroids
Disposition:
Discharge to home with outpatient follow-up
Year:
1953
Region / city:
Mississippi
Subject:
Mental Health / History
Document type:
Manuscript
Institution:
Whitfield
Author:
Fred Chaney
Target audience:
General public
Period of validity:
1953
Approval date:
1953
Date of changes:
1957
Year:
2021
Region / City:
Massachusetts
Topic:
COVID-19 Vaccine Breakthrough Cases
Document Type:
Memorandum
Organization:
Massachusetts Department of Public Health
Author:
Catherine M. Brown, DVM, MSc, MPH; Larry Madoff, MD
Target Audience:
Hospital-based Providers and Infection Preventionists
Date of Approval:
May 25, 2021
Date of Changes:
None
Context:
This document provides guidelines for reporting breakthrough COVID-19 cases that result in hospitalization or death in fully vaccinated individuals in Massachusetts.
Year:
Not specified
Region / Location:
Not specified
Field:
Neurobiology of swallowing, dysphagia management, pediatric feeding therapy
Document Type:
Clinical case study and therapy planning worksheet
Institution / Setting:
Clinical rehabilitation / feeding therapy context
Author:
Not specified
Patient Age:
18 months
Patient Condition:
Developmental delay following brain tumor resection with prolonged hospitalization and intubation
Clinical History:
Two-month hospital stay including two weeks of intubation; discharged with thickened liquids, soft and bite-sized diet, and nasogastric tube feeding
Primary Clinical Issues:
Aspiration of thin liquids, reduced oral intake, impaired chewing, oral motor weakness, attention and feeding behavior difficulties
Diagnostic Assessment:
Modified Barium Swallow Study (MBSS) / VFSS
Feeding Support:
NG tube with overnight continuous formula feeding
Target Areas:
Mealtime behavior, hunger regulation, oral sensory awareness, tongue lateralization, jaw strengthening, attention, self-feeding skills, straw drinking
Therapeutic Approaches:
Environmental adaptation, parent coaching, oral motor exercises, sensory stimulation, task-specific chewing practice, feeding routine structuring
Diet Level at Discharge:
Slightly thick liquids and soft & bite-sized solids
Key Symptoms:
Slow eating, distraction during meals, food pocketing, coughing with oral hygiene, aspiration of thin liquids, weak lip seal and intra-oral pressure
Year:
2006-2015
Region / city:
United Kingdom
Theme:
Environmental health, cardiovascular disease, noise exposure
Document type:
Research paper
Organization / institution:
Imperial College London, University of Leicester
Authors:
Garyfallos Konstantinoudis, Glory Atilola, Calvin Jephcote, Kathryn Adams, John Gulliver, Paul Elliott, Anna L Hansell, Marta Blangiardo
Target audience:
Researchers, public health professionals, policy makers
Period of validity:
2006-2015
Approval date:
Not specified
Date of changes:
Not specified
Year:
2026
Location:
University of Cincinnati Hospital, 8 East Unit
Subject:
Cystic Fibrosis inpatient care and hospital protocols
Document Type:
Patient guidance / hospital procedure
Institution:
UC Hospital Pulmonary Consult Service
Author:
CF Nurse Practitioner Angela Oder
Target Audience:
CF patients and their families
Admission Requirements:
Direct or scheduled CF admissions
Infection Control:
Droplet & Contact isolation, personal protective equipment required
Dietary Guidelines:
High calorie diet (3000 cal/day), extended menu for CF patients
Medical Monitoring:
Vital signs every 8 hours, weight 2–4 times per week, glucose monitoring as needed
Therapy and Exercise:
4 respiratory therapy sessions/day, encouraged physical activity, home IV setup guidance upon discharge
Follow-up:
Appointment within 2 weeks post-discharge
Type of document:
Official information for health professionals
Topic:
Respiratory syncytial virus vaccination in pregnancy
Vaccine name:
Abrysvo®
Target population:
Pregnant women
Gestational age for administration:
28–36 weeks of pregnancy
Country:
Australia
Health program:
National Immunisation Program
Availability under NIP:
From 3 February 2025
Notifiable disease status:
RSV notifiable in Victoria since 22 February 2022
Regulatory authority:
Therapeutic Goods Administration
Monitoring scheme:
Black Triangle Scheme
Related legislation:
Public Health and Wellbeing Act 2008
Intended audience:
Health professionals
Storage requirements:
+2°C to +8°C
Year:
2025
Country:
Australia
Region / City:
Victoria, Melbourne
Subject:
Respiratory syncytial virus immunisation during pregnancy
Document type:
Official guidance / fact sheet
Program:
Respiratory Syncytial Virus Mother and Infant Protection Program (RSV-MIPP)
Vaccine name:
Abrysvo® RSV vaccine
Target group:
Pregnant women at 28–36 weeks gestation
Intended users:
Immunisation providers
Dose and route:
Single 0.5 mL dose, intramuscular injection into the deltoid muscle
Co-administration:
Pertussis, influenza and COVID-19 vaccines
Storage conditions:
+2°C to +8°C prior to reconstitution
Issuing authority:
Victorian Government, Department of Health
Publisher address:
1 Treasury Place, Melbourne
Publication date:
January 2025
ISBN:
978-1-76131-797-2
Copyright holder:
State of Victoria, Australia
Year:
2025
Region / City:
Victoria, Australia
Topic:
Respiratory Syncytial Virus (RSV) Immunisation
Document Type:
Informational Leaflet
Organ / Institution:
Victorian Government, Department of Health
Author:
Victorian Government
Target Audience:
Parents and carers of infants and young children
Period of Action:
1 April 2025 to 30 September 2025
Approval Date:
February 2025
Date of Changes:
February 2025
Contextual Description:
A government-issued informational leaflet detailing RSV, its risks to infants, and the nirsevimab immunisation, including eligibility, administration, and availability.
Year:
2024
Region / city:
England
Subject:
Respiratory Syncytial Virus (RSV) Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Christina Wilson, Dr. Mary Ramsay, Greta Hayward
Target audience:
Healthcare practitioners, immunisation services
Valid from:
1 September 2024
Review date:
1 October 2026
Expiry date:
1 April 2027
Year:
2024
Region / city:
Wales
Theme:
Health, Vaccination
Document type:
Patient Group Direction (PGD)
Organization:
Welsh Medicines Advice Service
Author:
Liam Taylor, Dianne Burnett, Hawys Youlden
Target audience:
Registered healthcare professionals
Period of validity:
01 September 2024 – 31 August 2025
Approval date:
18 July 2024
Amendment date:
28 June 2024
Expiry date:
31 August 2025
Year:
2025
Region / City:
Victoria, Australia
Topic:
Immunisation, Respiratory Syncytial Virus (RSV)
Document type:
Consent form, Health guidance
Organization / Institution:
Victorian Government, Department of Health
Author:
Department of Health, Victoria
Target audience:
Parents/guardians of infants, Health professionals
Period of validity:
Ongoing
Date of approval:
April 2025
Date of changes:
Not specified
Year:
2015
Region / city:
Global
Topic:
Infectious diseases, sepsis, viral and bacterial co-infections
Document type:
Scientific article
Organization / institution:
Various medical institutions and researchers
Author:
Multiple authors
Target audience:
Medical professionals, researchers in infectious diseases
Effective period:
N/A
Approval date:
2015
Modification date:
N/A
Year:
2026
Region / City:
Tacoma, WA, USA
Topic:
Communicable diseases in children
Document Type:
Informational letter
Organization:
Tacoma-Pierce County Health Department
Author:
Communicable Disease Division
Target Audience:
Parents and guardians of children
Symptoms:
Cold-like symptoms, bronchiolitis, pneumonia, irritability, poor feeding, lethargy, cyanosis
Transmission:
Close contact with secretions, contaminated surfaces
Prevention Measures:
Hand washing, covering coughs and sneezes, ventilating home, sanitizing surfaces
Exclusion Guidelines:
Children not required to stay home unless too sick
Contact Information:
(253) 798-6410
Year:
2015
Region:
Oregon, USA
Topic:
Special Education, Vocational Training
Document Type:
Guidance Document
Organization:
Oregon Department of Education (ODE)
Audience:
Special education directors, secondary special education teachers, administrators, transition specialists
Related Case:
Lane vs. Brown Settlement Agreement
Target Group:
Students with intellectual and developmental disabilities
Content Focus:
Identification of inappropriate MSW activities, instructional sequence for pre-vocational training, transition services, IEP goal alignment
Year:
2025
Region / City:
Massachusetts
Topic:
PFAS, Environmental Health, Sustainable Procurement
Document Type:
Guide
Organization / Institution:
Responsible Purchasing Network for MA Operational Services Division
Author:
Responsible Purchasing Network
Effective Period:
June 2025
Approval Date:
June 2025
Last Modified Date:
June 2025
Year:
2018
Institution:
London School of Economics and Political Science
Department:
Department of Gender Studies
Type of document:
Guide / Academic Policy
Audience:
Students
Topic:
Plagiarism, Academic Integrity, Citation
Scope:
Undergraduate and Graduate Coursework
Document status:
Updated August 2018
Format:
Digital and Print
Note:
Year
Topic:
Business Writing
Document Type:
Educational Material
Target Audience:
Professionals in Business Communication
Year:
2020
Region / City:
United Kingdom
Topic:
Quality Improvement, Healthcare, Surgery
Document Type:
Research Article
Organization / Institution:
Northumbria Healthcare NHS Foundation Trust, University of York
Author:
Ashley Brian Scrimshire, Alison Booth, Caroline Fairhurst, Elizabeth Coleman, Ajay Malviya, Alwyn Kotze, Chris Tiplady, David Tate, Annie Laverty, Gillian Davis, Win Tadd, Belen Corbacho, Prof David J Torgerson, Dr Catriona McDaid, Prof Mike Reed
Target Audience:
Healthcare professionals, Researchers, Policy makers
Period of Action:
May 2018 - November 2019
Approval Date:
15 February 2018
Date of Last Revision:
November 2019